Clinical trials · New York, NY
Relapsed or Refractory Multiple Myeloma clinical trials in New York
We’re tracking 157 recruiting relapsed or refractory multiple myeloma studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
New York, New YorkAges 18 years+ - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
New York, New YorkAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
New York, New YorkAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
New York, New YorkAges 18 years+ - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
New York, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT07497399RecruitingPhase 2
Testing a diabetes drug for weight loss in MS
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
New York, New YorkAges 18–60 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
New York, New YorkAges 18 years+ - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
New York, New YorkAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
New York, New YorkAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
New York, New YorkAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
New York, New YorkAges 1–30 - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory lymphoma
This trial tests an investigational drug (TLN-121) for people with certain types of lymphoma that have come back or stopped responding to previous treatments. It aims to see if the drug can control the cancer and how safe it is.
New York, New YorkAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
New York, New YorkAges 18 years+ - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
New York, New YorkAges 18 years+ - NCT06901687RecruitingPhase 2
Home brain stimulation for depression in MS
This study tests whether a special, gentle brain stimulation device you can use at home (called tDCS) can help improve depression symptoms in people with multiple sclerosis. You will be supervised over video during the sessions to make sure everything goes smoothly.
New York, New YorkAges 18–65 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
New York, New YorkAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
New York, New YorkAges 12 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
New York, New YorkAges 18 years+ - NCT06177067RecruitingPhase 1
Study of 3 drugs for young AML patients with genetic changes
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
New York, New YorkAges 1–30 - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
New York, New YorkAges 18 years+ - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
New York, New YorkAges 18–65 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
New York, New YorkAges 18 years+ - NCT05372354RecruitingPhase 1/Phase 2
Testing a new multiple myeloma drug with other treatments
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
New York, New YorkAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Relapsed or Refractory Multiple Myeloma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 13 studies
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Bergen · 4 studies
- Memorial Sloan Kettering Monmouth · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Hackensack University Medical Center · 2 studies
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting relapsed or refractory multiple myeloma studies in New York.
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials near New York?
- Yes. We're currently tracking 157 recruiting relapsed or refractory multiple myeloma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.